<p>Kalaris Therapeutics Inc.（纳斯达克代码：KLRS - 获取免费报告）在 12 月份的空头头寸显著增加。截至 12 月 15 日，空头头寸总计为 503,479 股，比 11 月 30 日的 399,288 股增加了 26.1%。目前，该公司的 10.8% 股份被做空。根据平均每日交易量 145,440 股，当前的空头头寸比率为 3.5 天。</p>
<p>获取 <strong>Kalaris Therapeutics</strong> 的提醒：</p>
<h2>分析师设定新目标价</h2>
<p>几家研究公司最近对 KLRS 发布了报告。Citizens Jmp 在 11 月 3 日的研究报告中开始覆盖 Kalaris Therapeutics。他们对该股票给予了 “市场表现优于大盘” 的评级，并设定了 20.00 美元的目标价。Raymond James Financial 在 9 月 2 日的报告中开始覆盖 Kalaris Therapeutics。他们对该股票给予了 “强力买入” 的评级。华尔街 Zen 在 12 月 20 日的研究报告中将 Kalaris Therapeutics 的评级从 “卖出” 上调至 “持有”。Chardan Capital 在 12 月 23 日的研究报告中开始覆盖 Kalaris Therapeutics。他们给予该股票 “买入” 评级，并设定了 19.00 美元的目标价。最后，Weiss Ratings 在周一的研究报告中重新发布了 Kalaris Therapeutics 的 “卖出（d-）” 评级。一位研究分析师对该股票给予了强力买入评级，三位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Kalaris Therapeutics 的共识评级为 “适度买入”，平均目标价为 14.00 美元。</p>
<p><strong>阅读我们关于 Kalaris Therapeutics 的最新研究报告</strong></p>
<h2>机构投资者对 Kalaris Therapeutics 的看法</h2>
<p>几家对冲基金最近调整了对该公司的持股。Woodline Partners LP 在第三季度收购了 Kalaris Therapeutics 的新头寸，价值约为 1,394,000 美元。Belpointe Asset Management LLC 在第三季度收购了 Kalaris Therapeutics 的新股份，价值约为 231,000 美元。Fortis Capital Advisors LLC 在第三季度购买了 Kalaris Therapeutics 的新股份，价值约为 231,000 美元。XTX Topco Ltd 在第二季度收购了 Kalaris Therapeutics 的新头寸，价值约为 65,000 美元。最后，Bridgeway Capital Management LLC 在第三季度购买了 Kalaris Therapeutics 的新头寸，价值约为 130,000 美元。66.05% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Kalaris Therapeutics 股票下跌 8.2%</h2>
<p>Kalaris Therapeutics 的股票在周三开盘价为 8.38 美元。Kalaris Therapeutics 的 52 周低点为 2.14 美元，52 周高点为 12.90 美元。该公司的市值为 1.5671 亿美元，市盈率为-2.22，贝塔值为-0.04。该公司的 50 日移动平均价格为 6.63 美元，200 日移动平均价格为 4.67 美元。</p>
<p>Kalaris Therapeutics（纳斯达克代码：KLRS - 获取免费报告）最近在 11 月 12 日发布了季度财报。该公司报告的每股收益为（0.64 美元），超出分析师的共识预期（0.66 美元）0.02 美元。</p>
<h2>Kalaris Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Allovir, Inc 是一家临床阶段的细胞治疗公司，专注于研发异体、现成的多病毒特异性 T 细胞（VST）疗法，以预防和治疗严重的病毒相关疾病。该公司的主要产品是 posoleucel，一种异体、现成的 VST 疗法，用于治疗 BK 病毒、巨细胞病毒、腺病毒、埃布斯坦 - 巴尔病毒、人类疱疹病毒 6 和 JC 病毒。其临床前和临床开发的产品候选包括 ALVR106，用于呼吸道合胞病毒、流感、副流感病毒和人类副流感病毒；ALVR109 用于治疗 SARS-CoV-2 和 COVID-19；ALVR107 用于治疗乙型肝炎；以及 ALVR108。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Kalaris Therapeutics 更好</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人还未察觉）</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>[无脑黄金投资]：“给我看看更好的投资。”</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Kalaris Therapeutics 吗？</h2>
<p>在考虑 Kalaris Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Kalaris Therapeutics 并不在名单上。</p>
<p>虽然 Kalaris Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KLRS

<p>Kalaris Therapeutics Inc.（纳斯达克代码：KLRS）在 12 月份的空头头寸增加了 26.1%，总计达到 503,479 股。目前，其 10.8% 的股份被做空，基于 145,440 股的平均交易量，覆盖天数比率为 3.5 天。分析师对该股票的评级不一，普遍评级为 “适度买入”，平均目标价为 14.00 美元。该股票目前下跌 8.2%，交易价格为 8.38 美元，市值为 1.5671 亿美元，市盈率为-2.22</p>

<p>Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 503,479 shares, an increase of 26.1% from the November 30th total of 399,288 shares. Currently, 10.8% of the shares of the company are sold short. Based on an average daily trading volume, of 145,440 shares, the short-interest ratio is currently 3.5 days. Based on an average daily trading volume, of 145,440 shares, the short-interest ratio is currently 3.5 days. Currently, 10.8% of the shares of the company are sold short.</p>
<div class="lb-trans"><p>Kalaris Therapeutics Inc.（纳斯达克代码：KLRS - 获取免费报告）在 12 月份的空头头寸显著增加。截至 12 月 15 日，空头头寸总计为 503,479 股，比 11 月 30 日的 399,288 股增加了 26.1%。目前，该公司的 10.8% 股份被做空。根据平均每日交易量 145,440 股，当前的空头头寸比率为 3.5 天。</p>
</div><p>Get <strong>Kalaris Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Kalaris Therapeutics</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several research firms recently issued reports on KLRS. Citizens Jmp began coverage on Kalaris Therapeutics in a research report on Monday, November 3rd. They issued a &#34;market outperform&#34; rating and a $20.00 target price on the stock. Raymond James Financial began coverage on Kalaris Therapeutics in a report on Tuesday, September 2nd. They issued a &#34;strong-buy&#34; rating on the stock. Wall Street Zen upgraded Kalaris Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, December 20th. Chardan Capital started coverage on Kalaris Therapeutics in a research report on Tuesday, December 23rd. They issued a &#34;buy&#34; rating and a $19.00 target price on the stock. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Kalaris Therapeutics in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kalaris Therapeutics has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $14.00.</p>
<div class="lb-trans"><p>几家研究公司最近对 KLRS 发布了报告。Citizens Jmp 在 11 月 3 日的研究报告中开始覆盖 Kalaris Therapeutics。他们对该股票给予了 “市场表现优于大盘” 的评级，并设定了 20.00 美元的目标价。Raymond James Financial 在 9 月 2 日的报告中开始覆盖 Kalaris Therapeutics。他们对该股票给予了 “强力买入” 的评级。华尔街 Zen 在 12 月 20 日的研究报告中将 Kalaris Therapeutics 的评级从 “卖出” 上调至 “持有”。Chardan Capital 在 12 月 23 日的研究报告中开始覆盖 Kalaris Therapeutics。他们给予该股票 “买入” 评级，并设定了 19.00 美元的目标价。最后，Weiss Ratings 在周一的研究报告中重新发布了 Kalaris Therapeutics 的 “卖出（d-）” 评级。一位研究分析师对该股票给予了强力买入评级，三位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Kalaris Therapeutics 的共识评级为 “适度买入”，平均目标价为 14.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on Kalaris Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Kalaris Therapeutics 的最新研究报告</strong></p>
</div><h2>Institutional Investors Weigh In On Kalaris Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Kalaris Therapeutics 的看法</h2>
</div><p>Several hedge funds have recently modified their holdings of the company. Woodline Partners LP acquired a new position in Kalaris Therapeutics in the 3rd quarter worth about $1,394,000. Belpointe Asset Management LLC acquired a new stake in Kalaris Therapeutics in the third quarter valued at approximately $231,000. Fortis Capital Advisors LLC purchased a new stake in shares of Kalaris Therapeutics in the third quarter valued at approximately $231,000. XTX Topco Ltd acquired a new position in shares of Kalaris Therapeutics during the 2nd quarter worth approximately $65,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Kalaris Therapeutics during the 3rd quarter valued at approximately $130,000. 66.05% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对该公司的持股。Woodline Partners LP 在第三季度收购了 Kalaris Therapeutics 的新头寸，价值约为 1,394,000 美元。Belpointe Asset Management LLC 在第三季度收购了 Kalaris Therapeutics 的新股份，价值约为 231,000 美元。Fortis Capital Advisors LLC 在第三季度购买了 Kalaris Therapeutics 的新股份，价值约为 231,000 美元。XTX Topco Ltd 在第二季度收购了 Kalaris Therapeutics 的新头寸，价值约为 65,000 美元。最后，Bridgeway Capital Management LLC 在第三季度购买了 Kalaris Therapeutics 的新头寸，价值约为 130,000 美元。66.05% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Kalaris Therapeutics Stock Down 8.2%</h2>
<div class="lb-trans"><h2>Kalaris Therapeutics 股票下跌 8.2%</h2>
</div><p>Kalaris Therapeutics stock opened at $8.38 on Wednesday. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $12.90. The firm has a market cap of $156.71 million, a price-to-earnings ratio of -2.22 and a beta of -0.04. The business's 50-day moving average price is $6.63 and its 200 day moving average price is $4.67.</p>
<div class="lb-trans"><p>Kalaris Therapeutics 的股票在周三开盘价为 8.38 美元。Kalaris Therapeutics 的 52 周低点为 2.14 美元，52 周高点为 12.90 美元。该公司的市值为 1.5671 亿美元，市盈率为-2.22，贝塔值为-0.04。该公司的 50 日移动平均价格为 6.63 美元，200 日移动平均价格为 4.67 美元。</p>
</div><p>Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.02.</p>
<div class="lb-trans"><p>Kalaris Therapeutics（纳斯达克代码：KLRS - 获取免费报告）最近在 11 月 12 日发布了季度财报。该公司报告的每股收益为（0.64 美元），超出分析师的共识预期（0.66 美元）0.02 美元。</p>
</div><h2>Kalaris Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Kalaris Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.</p>
<div class="lb-trans"><p>Allovir, Inc 是一家临床阶段的细胞治疗公司，专注于研发异体、现成的多病毒特异性 T 细胞（VST）疗法，以预防和治疗严重的病毒相关疾病。该公司的主要产品是 posoleucel，一种异体、现成的 VST 疗法，用于治疗 BK 病毒、巨细胞病毒、腺病毒、埃布斯坦 - 巴尔病毒、人类疱疹病毒 6 和 JC 病毒。其临床前和临床开发的产品候选包括 ALVR106，用于呼吸道合胞病毒、流感、副流感病毒和人类副流感病毒；ALVR109 用于治疗 SARS-CoV-2 和 COVID-19；ALVR107 用于治疗乙型肝炎；以及 ALVR108。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Kalaris Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Kalaris Therapeutics 更好</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人还未察觉）</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>[无脑黄金投资]：“给我看看更好的投资。”</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kalaris Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Kalaris Therapeutics 吗？</h2>
</div><p>Before you consider Kalaris Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Kalaris Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kalaris Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Kalaris Therapeutics 并不在名单上。</p>
</div><p>While Kalaris Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kalaris Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kalaris Therapeutics Inc.（NASDAQ:KLRS）的空头头寸增加了 26.1%